Webinar Date/Time: Thursday, December 7, 2023 at 10am EST | 7am PST | 3pm GMT | 4pm CET
Empathizing with the people who are within the context of your protocol design begins with understanding how they think and feel. This webinar discusses the impact of patient-centricity on design and how design analytics can be applied to drive engagement. With patients included as a key element study design, reduced budgets, fewer deviations, and faster cycle times can be realized.
Register Free: https://www.pharmexec.com/pe/patient-centricity-design
Event Overview:
Empathy is the core of patient-centered clinical study design. Empathizing with the people who are within the context of your protocol design begins with understanding how they think and feel. This webinar discusses the impact of patient-centricity on design and how design analytics can be applied to drive engagement.
Combining data with the patient perspective provides a holistic view of patient decision-making criteria. This patient perspective can then be applied to optimize such things as diversity and inclusion, study procedures, and how endpoints are captured. With patients included as a key element study design, reduced budgets, fewer deviations, and faster cycle times can be realized.
Three key take-aways
In this webinar, a design analytics expert will present:
Speaker:
Ivan Petrov
Associate Design Analytics Director
IQVIA
Ivan Petrov, based in the IQVIA Sofia office, has experience in both healthcare and FMCG consulting. He holds a MBA with a specialization in Strategic Management from Sofia University. Prior to joining IQVIA, he was a part of the Nielsen consulting team, leading the business for Bulgaria and advising FMCG companies by creating tailor-made solutions to meet client goals.
Ivan has been with IQVIA since 2015, closely collaborating with a multitude of pharmaceutical companies, regulatory organs, payers, pharmacy chains, and wholesalers in various therapeutic areas on all stages of client engagement — from lead generation and initial sale through project management and analytics, to final deliverable implementation. Currently, Ivan is part of the Design Analytics team where he helps clients optimize their study design, with a focus on the patient perspective, ensuring patient voice is heard throughout the clinical development continuum.
Register Free: https://www.pharmexec.com/pe/patient-centricity-design
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.